Stage III Ovarian Epithelial Cancer Completed Phase 2 Trials for Tanespimycin (DB05134)

IndicationStatusPhase
DBCOND0028510 (Stage III Ovarian Epithelial Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00093496Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity CancerTreatment